title: Antidiabetic activity and molecular docking of fructooligosaccharides produced by Aureobasidium pullulans in poloxamer-407-induced T2DM rats.
abstract: This study evaluated the beneficial effects of fructooligosaccharide (FOS) intake from Aureobasidium pullulans using poloxamer-407 (PX-407) induced type 2 diabetes mellitus (T2DM) in rat. Administration of FOS enhanced enzymatic activities of catalase and glutathione reductase in a dose-dependent manner. Significant reduction in fasting plasma triacylglycerol and very low-density lipoprotein level coupled with slight increase in fasting plasma insulin level was observed. Significant decrease in severe glucosuria, proteinuria, blood creatinine, urea and advanced glycation end products was also observed. Supplementation of FOS increased glucagon like peptide-1 content as well as Bifidobacteria and Lactobacilli populations in the caecum. Molecular docking by Gold and Glide software revealed that three sugar types present in the FOS (1-kestose, nystose, and 1-β-fructofuranosyl nystose) are potent dipeptidyl peptidase-IV inhibitors as well as peroxisome proliferator-activated receptor-gamma agonists. This work indicates that FOS can be positioned as a nutraceutical product, beneficial in diabetes-associated metabolic abnormalities.
authors.affiliation: Department of Biochemistry, Patna University, Patna 800005, Bihar, India. sudhanshu_bharti@rediffmail.com
authors.forename: Sudhanshu Kumar
authors.initials: SK
authors.lastname: Bharti
authors.forename: Supriya
authors.initials: S
authors.lastname: Krishnan
authors.forename: Amit
authors.initials: A
authors.lastname: Kumar
authors.forename: Kaushal Kishore
authors.initials: KK
authors.lastname: Rajak
authors.forename: Krishna
authors.initials: K
authors.lastname: Murari
authors.forename: Binod Kumar
authors.initials: BK
authors.lastname: Bharti
authors.forename: Ashok Kumar
authors.initials: AK
authors.lastname: Gupta
mesh_terms: D000818:Animals; D001203:Ascomycota / Q000737:chemistry / Q000378:metabolism*; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000737:chemistry* / Q000378:metabolism; D007328:Insulin / Q000378:metabolism; D008297:Male; D062105:Molecular Docking Simulation; D015394:Molecular Structure; D009844:Oligosaccharides / Q000008:administration & dosage* / Q000737:chemistry* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000378:metabolism
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D009844:Oligosaccharides; D014280:Triglycerides; C116580:fructooligosaccharide